Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab
Open Access
- 31 July 2006
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 134 (5), 475-484
- https://doi.org/10.1111/j.1365-2141.2006.06210.x
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a common lymphoma entity. Although a significant amount of DLBCL patients can be cured with modern chemotherapeutic regimens, a substantial proportion of patients die because of progressive disease. Therefore, new therapeutic strategies are clearly needed. Inhibitors of mTOR [mammalian target of rapamycin (Rap)] represent a new class of antiproliferative drugs with applications as immunosuppressive and anticancer agents. Extensive safety data exist on the mTOR inhibitor RAD001, which is already approved as an immunosuppressant in organ transplant recipients. Rap and RAD001 inhibited cell cycle progression in DLBCL cells by inducing a G1 arrest without inducing apoptosis. Phosphorylation of the main targets of mTOR, p70 s6 kinase and 4-EBP-1 was reduced in cells cultured in the presence of RAD001. Cell cycle arrest was accompanied by reduced phosphorylation of the retinoblastoma protein (RB) as well as reduced expression of cyclin D3 and A in all cell lines. Although the effect of the chemotherapeutic agent vincristine (vin) was not enhanced by RAD001, rituximab-induced cytotoxicity was augmented in the rituximab-sensitive cell lines. mTOR inhibition is a promising therapeutic strategy in DLBCL by inducing a G1 arrest and augments rituximab-induced cytotoxicity. Therefore, combination of these drugs might be an interesting new therapeutic approach in DLBCL patients.This publication has 32 references indexed in Scilit:
- Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell LymphomaJournal of Clinical Oncology, 2005
- Evidence for Cyclin D3 as a Novel Target of Rapamycin in Human T LymphocytesOnline Journal of Public Health Informatics, 2004
- Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor FlavopiridolClinical Cancer Research, 2004
- Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell SupportThe New England Journal of Medicine, 2004
- Mammalian target of rapamycin inhibition as therapy for hematologic malignanciesCancer, 2004
- Rapamycin Inhibits the Growth and Metastatic Progression of Non-Small Cell Lung CancerClinical Cancer Research, 2004
- Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin LymphomaThe Journal of Experimental Medicine, 2003
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsThe New England Journal of Medicine, 2003
- Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2003
- Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites.The Journal of Experimental Medicine, 1991